Related Experiment Video

Updated: Apr 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in

Sudesh Prajapathi1, Kunal Mahajan2, Aditi Mohta3

  • 1Department of Cardiology All India Institute of Medical Sciences Bhopal Madhya Pradesh India.

Journal of the American Heart Association
|April 22, 2026
PubMed

Insights

Obicetrapib, a novel CETP inhibitor, offers effective oral lipid lowering for patients not reaching cholesterol targets. Clinical trials show promising efficacy and safety, positioning it as a valuable adjunct therapy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Atherosclerotic cardiovascular diseases are a leading cause of death globally.
  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary driver.
  • Current therapies leave many high-risk patients with suboptimal LDL-C control.

Purpose of the Study:

  • To review the development and clinical evidence of obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor.
  • To assess its efficacy, safety, and potential role in managing dyslipidemia.
  • To compare obicetrapib with existing lipid-lowering treatments.

Main Methods:

  • Comprehensive review of clinical trials (TULIP, ROSE, ROSE2, BROADWAY, BROOKLYN, TANDEM, PREVAIL).
  • Analysis of obicetrapib's mechanism of action, pharmacokinetics, and pharmacodynamics.
  • Comparative assessment of efficacy, safety, and tolerability data.

Main Results:

  • Obicetrapib demonstrates robust lipid-lowering capabilities.
  • Early clinical data suggest a favorable safety profile compared to earlier CETP inhibitors.
  • Ongoing trials are evaluating its cardiovascular benefits.

Conclusions:

  • Obicetrapib represents a promising new oral therapy for dyslipidemia.
  • It addresses an unmet need for effective adjunct lipid-lowering treatments.
  • Further data from cardiovascular outcomes trials will clarify its long-term clinical utility.

Keywords:
LDL‐C loweringatherosclerotic cardiovascular diseasecholesteryl ester transfer protein inhibitorslipid‐lowering therapyobicetrapib

More Related Videos

Cholesterol Efflux Assay07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.4K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

8.5K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.2K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
649
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K